Replies to post #71102 on NanoViricides Inc. (NNVC)

[Puffer]

I am referring to the typical period of time between submitting the letter of intent to file (Jul 1st) to the actual filing, as referenced here --





Mon, Jul 22, 2013 7:00 AM EDT..


WEST HAVEN, Conn.--(BUSINESS WIRE)--

NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has been notified that the Committee on Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA) has appointed a team of clinical coordinators for the purpose of reviewing the Company’s upcoming orphan drug designation application for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

COMP has appointed this team in response to the Company’s submission of a letter of intent to file an Orphan Drug Application with the European Medicines Agency (EMA) for DengueCide™. NanoViricides intends to file this application after the appropriate notice period (usually 60 days) has expired. The actual application will need to be translated into 27 different languages prior to submission.